05.07.2021
Regenics - changes Management and Board
July 5th 2021: Regenics appoints new CEO and chairman BoD.          Karl Bryn, CEO.    Jan Alfheim, Chair BoD.  
14.06.2021
Subscription rights declared
14.06.2021
General Assembly 2021
 
29.03.2021
Dagens Medisin
10.03.2021
EU Invest Horizon - Series A process Regenics
EU Invest Horizon - Series A program.
21.12.2020
EGM January 4th 2021
January 4th 2021 Extraordinary Annual Meeting January 4th 2021. (Video/phone) (only one agenda point: VPS registration of shares)  
25.11.2020
Regenics presents at Marine Biotechnology Conference 2020 Sweden
02.09.2020
New Board of Directors
August 20th 2020   August 20th 2020 Regenics AS General Assembly June 24th 2020 has nominated a new Board of Directors: Tore Heldrup Rasmussen, reelected Wilhelm Holst, reelected Harald Nordal, new Jan Alfheim, new On the new Boards...
01.08.2020
Regenics new office at Oslo Science Park
August 1st 2020  Regenics AS expands its laboratory footprint with new lab space at ShareLab at Forkningsparken, Oslo.   
17.06.2020
Annual Meeting 2020
June 24th 2020 Notice of Annual Meeting took place June 24th 2020 at 16.00. Companys site Karvesvingen 2. 
17.06.2020
AquaHeal 3D update (EU funded project)
Regenics updates on the 17.3 mill NOK coordination of EU BlueBio Cofund R&D project. RISE (Swe) and Charles River (US) partners
24.03.2020
Regenics AS secures loan from Innovation Norway
Regenics AS secures loan facility from Innovation Norway
01.01.2020
Regenics awarded 17.3 mill NOK to coordinate EU BlueBio Cofund R&D project
Regenics awarded 17.3 mill NOK to coordinate EU BlueBio Cofund R&D project. RISE (Swe) and Charles River (US) partners
25.09.2019
Board Meeting No 6 2019
Board Meeting No 6. September 25th 2019
12.08.2019
US Patent - Notice of Allowance
US patent - Notice of Allowance
23.07.2019
Canadian Patent - Notice of Allowance
Canadian Patent - Notice of Allowance

Page 1 of 8   >  >>

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.